美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的疗效及对炎性因子的影响
|
摘要
目的探讨美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的疗效及其对炎性因子的影响。方法选取2017年1月～2018年1月我院收治的溃疡性结肠炎患者80例,随机分为两组,每组各40例,两组患者均予常规对症治疗,同时两组均予美沙拉嗪缓释颗粒,观察组同时加用双歧三联活菌胶囊,治疗后比较两组患者治疗后的临床疗效,以及两组患者治疗前后TNF-α、IL-10水平的变化情况及两组患者治疗前后的临床症状积分变化情况。结果观察组治疗后的总有效率为95.00%,显著高于对照组的总有效率70.00%,两组疗效比较差异具有显著性(P<0.05)。治疗后,两组患者的炎性因子TNF-α、IL-10水平较治疗前显著降低(P<0.05)。且观察组患者治疗后的TNF-α、IL-10水平显著低于对照组(P<0.05)。观察组患者治疗后的临床症状积分为(2.56±0.85)分,与治疗前及对照组比较,差异有统计学意义(P<0.05)。结论美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎疗效确切,且可以抑制炎症反应,值得临床推广和应用。
Objective To investigate the efficacy of mesalazine combined with bifidobacteria in the treatment of ulcerative colitis and its effect on inflammatory factors. Methods 80 patients with ulcerative colitis admitted in our hospital from January 2017 to January 2018 were randomly divided into observation group and control group, with 40 cases in each group. Both groups were treated with conventional symptomatic treatment. All of them were treated with mesalazine sustained-release granules. The observation group was also treated with bifidobacteria capsules. The clinical effects after treatment, the changes of TNF-α and IL-10 levels and the changes in clinical symptom scores before and after treatment of the two groups were compared. Results The total effective rate of the observation group was 95.00%,which was significantly higher than that of the control group(70.00%). The difference between the two groups was significant(P<0.05). After treatment, the levels of inflammatory factors TNF-α and IL-10 in the two groups were significantly lower than those before treatment(P<0.05). The levels of TNF-α and IL-10 in the observation group were significantly lower than those in the control group, and the difference between the groups was significant(P<0.05). The clinical symptom score of the observation group was(2.56±0.85)points after treatment,which was significantly different from that of the control group and before treatment(P<0.05). Conclusion Mesalazine combined with bifidobacteria is effective in the treatment of ulcerative colitis, which can inhibit the inflammatory response, and is worthy of clinical promotion and application.
Objective To investigate the efficacy of mesalazine combined with bifidobacteria in the treatment of ulcerative colitis and its effect on inflammatory factors. Methods 80 patients with ulcerative colitis admitted in our hospital from January 2017 to January 2018 were randomly divided into observation group and control group, with 40 cases in each group. Both groups were treated with conventional symptomatic treatment. All of them were treated with mesalazine sustained-release granules. The observation group was also treated with bifidobacteria capsules. The clinical effects after treatment, the changes of TNF-α and IL-10 levels and the changes in clinical symptom scores before and after treatment of the two groups were compared. Results The total effective rate of the observation group was 95.00%,which was significantly higher than that of the control group(70.00%). The difference between the two groups was significant(P<0.05). After treatment, the levels of inflammatory factors TNF-α and IL-10 in the two groups were significantly lower than those before treatment(P<0.05). The levels of TNF-α and IL-10 in the observation group were significantly lower than those in the control group, and the difference between the groups was significant(P<0.05). The clinical symptom score of the observation group was(2.56±0.85)points after treatment,which was significantly different from that of the control group and before treatment(P<0.05). Conclusion Mesalazine combined with bifidobacteria is effective in the treatment of ulcerative colitis, which can inhibit the inflammatory response, and is worthy of clinical promotion and application.
引文
[1]陆青峰,毛迎春.美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的临床疗效观察[J].数理医药学杂志,2015,28(9):1363-1364
[2]宋晓华,郑英兰.美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎效果[J].齐鲁医学杂志,2011,26(2):145-147.
[3]张桥东.美沙拉嗪颗粒与枯草杆菌二联活茵肠溶胶囊联合治疗溃疡性结肠炎的临床疗效分析[J].齐齐哈尔医学院学报,2015,10(10):1427-1429
[4]黄慧民,黄勤.美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的效果对比研究[J].中国当代医药,2014,21(11):85-86.
[5]钟雨霞.美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的疗效观察[J].黑龙江医药,2015,28(3):561-562.
[6]丁丽华.美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎的临床效果观察[J].社区医学杂志,2025,13(11):42-44.
[7]柴元亮.双歧三联活菌联合美沙拉嗪治疗轻中度溃疡性结肠炎疗效分析[J].中国现代药物应用,2014,8(1):120-121.
[8]歧红阳,王云溪,肖占宇.美沙拉嗪联合双歧杆菌四联活菌治疗溃疡性结肠炎的临床效果评价[J].职业与健康,2011,27(12):1431-1432.
[9]李豪,杨永志,袁耀宗,等.双歧杆菌三联活菌制剂治疗溃疡性结肠炎临床疗效Meta分析[J].中国实用内科杂志,2016,36(10):919-920..
[10]Guandalini S,Cernat E,Moscoso D.Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children[J].Benef Microbes,2015,6(2):209-217.
[11]张艳.美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎的疗效分析[J].中国现代医生,2017,55(31):43-45.
[12]徐正元.溃疡性结肠炎154例临床分析[J].中国社区医师(医学专业),2013,15(2):114-115.
[13]孙贵张.微生态制剂联合美沙拉嗪治疗20例溃疡性结肠炎的临床观察[J].上海医药,2013,34(7):25-26.
[14]徐红,李浩,陈世雄.培菲康与美沙拉嗪联合治疗溃疡性结肠炎的临床效果观察[J].齐齐哈尔医学院学报,2012,33(16):2194-2195.
[15]姜宗丹,张振玉,孔超美,等.美沙拉嗪对溃疡性结肠炎患者肠粘膜紧密连接蛋白表达的影响[J].胃肠病学,2013,18(8):462-464.
[16]叶彬,樊德利.蒲芩败酱汤与美沙拉嗪灌肠对溃疡性结肠炎患者血清TNF-a及IL-10的影响[J].浙江中医杂志,2013,48(7):476-477.
[17]Scarpa M,Castagliuolo I,Castoro C,et al.lnflammatorv colonic carci-nogenesis:A review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis[J]World J Gastroenterol,2014,20(22):6774-6758.
[18]祝林,曾宏,余帮龙,等.双歧三联活菌联合美沙拉唪治疗溃疡性结肠炎疗效观察[J].现代诊断与治疗,2016,27(4):593-594.
[19]高山.溃疡性结肠炎临床疗效对比观察[J].中外医学研究,2013,11(15):29-30.
[20]刘柱.观察美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的临床效果[J].临床合理用药,2015,8(1):81-82.
[21]华洪文.美沙拉嗪联合益生菌治疗溃疡性结肠炎疗效分析[J].广东微量元素科学,2015,22(9):47-48.
[22]霍丽娟,安丽婷,师永盛,等.美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的临床疗效观察[J].中华消化杂志,2012,32(8):523-527.
[23]赵雅琴,奚维东.美沙拉嗪联合金双歧治疗溃疡性结肠炎患者的疗效及对细胞因子的影响[J].医学综述,2015,21(12):2293-2294.
[24]赵冰.双歧三联活菌联合美沙拉嗪治疗溃疡性结肠炎的临床疗效及对血清炎症因子的影响[J].中国现代医药杂志,2016,18(5):65-66.
[25]赵静,易静.美沙拉嗪联合双歧杆菌三联活菌胶囊治疗溃疡性结肠炎及对患者血清hs-CRP、ESR、PLT、D-二聚体的影响[J].中国医学创新,2017,14(35):114-117.
[26]王明蕾.美沙拉嗪联合双岐杆菌三联活菌治疗溃疡性结肠炎的疗效及对炎症因子水平的影响[J].中国医药科学,2017,7(18):43-45.
[27]李开学,曾理,舒晴.益生菌联合美沙拉嗪治疗轻、中度活动期溃疡性结肠炎的效果及安全性[J].中国医学创新,2017,14(8):56-59.
[2]宋晓华,郑英兰.美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎效果[J].齐鲁医学杂志,2011,26(2):145-147.
[3]张桥东.美沙拉嗪颗粒与枯草杆菌二联活茵肠溶胶囊联合治疗溃疡性结肠炎的临床疗效分析[J].齐齐哈尔医学院学报,2015,10(10):1427-1429
[4]黄慧民,黄勤.美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的效果对比研究[J].中国当代医药,2014,21(11):85-86.
[5]钟雨霞.美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的疗效观察[J].黑龙江医药,2015,28(3):561-562.
[6]丁丽华.美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎的临床效果观察[J].社区医学杂志,2025,13(11):42-44.
[7]柴元亮.双歧三联活菌联合美沙拉嗪治疗轻中度溃疡性结肠炎疗效分析[J].中国现代药物应用,2014,8(1):120-121.
[8]歧红阳,王云溪,肖占宇.美沙拉嗪联合双歧杆菌四联活菌治疗溃疡性结肠炎的临床效果评价[J].职业与健康,2011,27(12):1431-1432.
[9]李豪,杨永志,袁耀宗,等.双歧杆菌三联活菌制剂治疗溃疡性结肠炎临床疗效Meta分析[J].中国实用内科杂志,2016,36(10):919-920..
[10]Guandalini S,Cernat E,Moscoso D.Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children[J].Benef Microbes,2015,6(2):209-217.
[11]张艳.美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎的疗效分析[J].中国现代医生,2017,55(31):43-45.
[12]徐正元.溃疡性结肠炎154例临床分析[J].中国社区医师(医学专业),2013,15(2):114-115.
[13]孙贵张.微生态制剂联合美沙拉嗪治疗20例溃疡性结肠炎的临床观察[J].上海医药,2013,34(7):25-26.
[14]徐红,李浩,陈世雄.培菲康与美沙拉嗪联合治疗溃疡性结肠炎的临床效果观察[J].齐齐哈尔医学院学报,2012,33(16):2194-2195.
[15]姜宗丹,张振玉,孔超美,等.美沙拉嗪对溃疡性结肠炎患者肠粘膜紧密连接蛋白表达的影响[J].胃肠病学,2013,18(8):462-464.
[16]叶彬,樊德利.蒲芩败酱汤与美沙拉嗪灌肠对溃疡性结肠炎患者血清TNF-a及IL-10的影响[J].浙江中医杂志,2013,48(7):476-477.
[17]Scarpa M,Castagliuolo I,Castoro C,et al.lnflammatorv colonic carci-nogenesis:A review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis[J]World J Gastroenterol,2014,20(22):6774-6758.
[18]祝林,曾宏,余帮龙,等.双歧三联活菌联合美沙拉唪治疗溃疡性结肠炎疗效观察[J].现代诊断与治疗,2016,27(4):593-594.
[19]高山.溃疡性结肠炎临床疗效对比观察[J].中外医学研究,2013,11(15):29-30.
[20]刘柱.观察美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的临床效果[J].临床合理用药,2015,8(1):81-82.
[21]华洪文.美沙拉嗪联合益生菌治疗溃疡性结肠炎疗效分析[J].广东微量元素科学,2015,22(9):47-48.
[22]霍丽娟,安丽婷,师永盛,等.美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的临床疗效观察[J].中华消化杂志,2012,32(8):523-527.
[23]赵雅琴,奚维东.美沙拉嗪联合金双歧治疗溃疡性结肠炎患者的疗效及对细胞因子的影响[J].医学综述,2015,21(12):2293-2294.
[24]赵冰.双歧三联活菌联合美沙拉嗪治疗溃疡性结肠炎的临床疗效及对血清炎症因子的影响[J].中国现代医药杂志,2016,18(5):65-66.
[25]赵静,易静.美沙拉嗪联合双歧杆菌三联活菌胶囊治疗溃疡性结肠炎及对患者血清hs-CRP、ESR、PLT、D-二聚体的影响[J].中国医学创新,2017,14(35):114-117.
[26]王明蕾.美沙拉嗪联合双岐杆菌三联活菌治疗溃疡性结肠炎的疗效及对炎症因子水平的影响[J].中国医药科学,2017,7(18):43-45.
[27]李开学,曾理,舒晴.益生菌联合美沙拉嗪治疗轻、中度活动期溃疡性结肠炎的效果及安全性[J].中国医学创新,2017,14(8):56-59.